Orgenesis Inc.

ORGS
About the company

Orgenesis Inc., a biotech company, focuses on cell and gene therapies in the United States. It operates through two segments: Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare model, POCare network consisting of research institutes and hospitals.

Country: United StatesPrice: $0.38Market Cap: $3.7M

Investment snapshot

12%positive consensus
Scored 1d ago

Positive

2

BUY / PASS

Neutral / negative

3 / 11

NEUTRAL / FAIL

Median fair value

$101.40

+26940.0% vs price

Models with upside

3 / 17

Positive margin of safety

Strongest signal

Models split on ORGS at $0.38 — fair values range $0.33–$286.00

Key risk

No clean pass — all 8 investors flag at least one efficiency criterion

Framework analysis

VerdictMeaning
BUYPositive purchase signal: the framework's buy requirements are met.
PASSThe company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRALNeither a positive nor negative conclusion. It does not mean to hold an existing position.
FAILThe company does not clear the framework's requirements.
RankedRanked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

MetricGraham

Defensive Value

Buffett

Quality Compounder

Lynch

GARP

Greenblatt

Magic Formula

Piotroski

F-Score

Dreman

Contrarian Value

Munger

Quality Focus

Pabrai

Dhandho Framework

Akre

Three-Legged Stool

Marks

Risk-Aware Value

Ackman

Activist Value

Templeton

Global Bargain Hunter

Sleep

Scale Economies Shared

Asness

Systematic Factors

Neff

Low-P/E Total Return

Schloss

Asset-Value Discipline

O'Shaughnessy

Systematic Factor Composite

VerdictFAILFAILFAILNot rankedPASSFAILPASSNEUTRALFAILFAILFAILFAILFAILNEUTRALFAILFAILNEUTRAL
Score
AnalysisChecking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…
Intrinsic Value (annual)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Margin of SafetyN/AN/A+99.9%N/AN/A+99.8%N/AN/AN/A+99.2%N/A-13.6%N/AN/AN/AN/AN/A
Financial Basis

Annual history · FY 2024

Latest source filing: 2026-03-26

Score computed: 2026-11-14

Annual history · FY 2024

Latest source filing: 2026-03-26

Score computed: 2026-11-14

Annual history · FY 2024

Latest source filing: 2026-03-26

Score computed: 2026-11-14

Annual history · FY 2024

Latest source filing: 2026-03-26

Score computed: 2026-11-14

Annual history · FY 2024

Latest source filing: 2026-03-26

Score computed: 2026-11-14

Annual history · FY 2024 · Market data at 2026-11-01

Latest source filing: 2026-03-26

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2024

Latest source filing: 2026-03-26

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2024

Latest source filing: 2026-03-26

Score computed: 2026-11-14

Annual history · FY 2024 · Qualitative assessment

Latest source filing: 2026-03-26

Score computed: 2026-11-14

Annual history · FY 2024 · Qualitative assessment

Latest source filing: 2026-03-26

Score computed: 2026-11-14

Annual history · FY 2024 · Market data at 2026-11-01

Latest source filing: 2026-03-26

Score computed: 2026-11-14

Annual history · FY 2024 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-03-26

Score computed: 2026-11-14

Annual history · FY 2024 · Qualitative assessment

Latest source filing: 2026-03-26

Score computed: 2026-11-14

Annual history · FY 2024 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-03-26

Score computed: 2026-11-14

Annual history · FY 2024

Latest source filing: 2026-03-26

Score computed: 2026-11-14

Annual history · FY 2024

Latest source filing: 2026-03-26

Score computed: 2026-11-14

Annual history · FY 2024 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-03-26

Score computed: 2026-11-14

Where It Passes

  • Valuation models75% pass✓ 3✗ 1▾

    Models split on ORGS at $0.38 — fair values range $0.33–$286.00

    Lynch fair value$286.00
    ✓Lynch+99.9% margin vs $0.38
    Dreman fair value$155.55
    ✓Dreman+99.8% margin vs $0.38
    Marks fair value$47.25
    ✓Marks+99.2% margin vs $0.38
    Templeton fair value$0.33
    ✗Templeton-13.6% margin vs $0.38

Where It Falls Short

  • Efficiency0% pass✓ 1✗ 10▾

    No clean pass — all 8 investors flag at least one efficiency criterion

    Current Ratio0.03
    ✗Graham>= 2.0
    ROIC (3-5 yr avg)-110.7%
    ✗Buffett> 10%
    ROIC - WACC-120.7%
    ✗BuffettPositive (WACC = 10%)
    EBIT / (NWC + Net Fixed Assets)N/A (invested capital <= 0)
    ✗Greenblatt> 25%
    Current Ratio Change YoY0.25 -> 0.03
    ✗PiotroskiIncreased YoY
    Revenue / Total Assets Change YoY0.04x -> 0.77x
    ✓PiotroskiImproved YoY
    Current Assets / Current Liabilities0.03
    ✗Dreman> 1.5
    Return on Invested CapitalN/A (non-positive invested capital)
    ✗Munger> 15%
    ROIC (high and growing)FY2022: ROIC=-17.6%; FY2023: ROIC=unavailable; FY2024: ROIC=unavailable
    ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
    Reinvestment Rate x ROIC
    ✗AkreReinvestment Rate * ROIC > 10%
    ROIC (5-year)0/3 years above 12% (latest -17.6%)
    ✗SleepROIC > 12% in a majority of years
  • Debt & Leverage8% pass✓ 1✗ 14▾

    11 of 12 flag ORGS's debt & leverage — Graham, Buffett, Lynch +8 more

    LT Debt vs Net Current Assets
    ✗GrahamLT Debt <= Net Current Assets
    Debt/Equity & Interest CoverageD/E: N/A (negative equity), IC: -9942.0x
    ✗BuffettD/E < 0.5 AND Interest Coverage > 5x
    Total Debt / EquityN/A (negative equity)
    ✗Lynch< 0.33
    Cash - Long-term Debt
    ✗LynchPositive preferred
    LT Debt / Total Assets Change0.00% -> 0.00%
    ✓PiotroskiDecreased YoY
    Current Assets / Current Liabilities0.03
    ✗Dreman> 1.5✗SchlossCurrent ratio >= 1.50x (app cutoff)
    Total Debt / Shareholders' Equity
    ✗Dreman< 0.8✗Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✗SchlossD/E < 1.00x
    Debt LevelsN/A (non-positive equity)
    ✗MungerDebt/Equity < 0.5✗AkreDebt/Equity < 0.3
    Interest Coverage & Debt/EBITDAIC=-9942.0x, D/EBITDA=N/A
    ✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x
    Total Debt / Shareholders Equity
    ✗Ackman<= 1.0
    Negative debt-to-equity (higher means less debt)
    ✗AsnessTop 30% of eligible cross-section
  • Cash Flow10% pass✓ 2✗ 10▾

    9 of 10 flag ORGS's cash flow — Buffett, Lynch, Piotroski +6 more

    Free Cash Flow Proxy$-46.3M
    ✗BuffettPositive and growing
    FCF Positive and Growing$-17.3M
    ✗LynchPositive and growing
    Operating Cash Flow$-17.1M
    ✗PiotroskiCFO > 0
    (CFO / Total Assets) vs ROACFO/Assets=-1263.95%, ROA=-3565.14%
    ✓PiotroskiCFO/Assets > ROA
    Price / (CFO / Shares)
    ✗Dreman< 8x
    P/E or FCF YieldP/E=0.0x, FCF Yield=-471.8%
    ✓PabraiP/E < 15 or FCF Yield > 10%
    FCF Positive0/14 years FCF positive
    ✗MarksPositive FCF in majority of recent years
    (OCF - CapEx) / Market Cap
    ✗Ackman>= 4%
    Price / FCF per Share
    ✗Ackman<= 25
    Positive Operating Cash Flow frequency0/15 years positive
    ✗SleepPositive OCF in >= 70% of available years
    Operating Cash Flow - Capital Expenditures$-17.3M
    ✗Neff> $0 (app proxy for a strong fundamental case)
    (Operating cash flow - capex) / market capitalization-471.83%; #4339/4519 (top 96.0%)
    ✗OshaughnessyTop 10% of eligible cross-section
  • Profitability13% pass✓ 10✗ 25▾

    14 of 16 flag ORGS's profitability — Graham, Buffett, Lynch +11 more

    Positive EPS (10 years)10/15 years positive
    ✗GrahamPositive EPS every year for 10 years
    EPS Growth (3-yr avg, 10-yr window)15388.9%
    ✓Graham>= 33% growth
    Net Income Positive (10+ years)2/15 years positive
    ✗BuffettPositive every year for 10+ years
    ROE (up to 5-year arithmetic mean)54.3%
    ✓Buffett> 15% arithmetic mean (app rule)
    Operating Margin (10-yr trend)-3842.3% (latest)
    ✗BuffettStable or rising over 10 years
    Free Cash Flow Proxy$-46.3M
    ✗BuffettPositive and growing
    Earnings Variance (10-yr CoV)3.41
    ✗BuffettCoV < 0.3
    Retained Earnings Effectiveness
    ✗Buffett$1 retained -> > $1 market value created
    Basic earnings-growth PEG (dividends excluded)0.00
    ✓Lynch< 1.0 (ideally < 0.5)
    3-5 Year EPS CAGR149.1%
    ✓Lynch15-30% (Fast Grower); > 0% to pass
    ROEN/A (negative equity)
    ✗Lynch> 15%
    EBIT / Enterprise Value-258.9%
    ✗Greenblatt> 10%
    Earnings Yield + ROC AssessmentEY=-258.9%, ROC=N/A (invested capital <= 0)
    ✗GreenblattBoth EY > 10% and ROC > 25%
    Net Income / Total Assets-3565.14%
    ✗PiotroskiROA > 0
    ROA Change YoY-380.44% -> -3565.14% (delta: -3184.70%)
    ✗PiotroskiCurrent ROA > Prior ROA
    (CFO / Total Assets) vs ROACFO/Assets=-1263.95%, ROA=-3565.14%
    ✓PiotroskiCFO/Assets > ROA
    Gross Margin Change YoY-1080.2% -> -86.3%
    ✓PiotroskiImproved YoY
    Pre-Tax Income / Revenue-4726.2%
    ✗Dreman>= 8%
    Net Income / Shareholders' Equity
    ✗Dreman> 12%
    Margin of SafetyP/E=0.0x
    ✓PabraiP/B < 1.5 or P/E < 15
    Return on Equity-32.9% (3-yr avg)
    ✗AkreROE > 20% (3-year avg)
    Discount to Intrinsic Value99.5% (IV=$69.70 vs Price=$0.38)
    ✓Marks>= 20% below intrinsic value
    Positive Net Income Frequency2/15 years positive
    ✗MarksPositive net income in >= 7 of last 10 years
    Operating Income / Revenue-3842.3%
    ✗Ackman>= 15%
    Net Income / Shareholders Equity
    ✗Ackman>= 15%
    5-Year EPS CAGR149.1% CAGR over 3 years
    ✓Templeton> 0% (5-year EPS CAGR)
    Operating Margin Trend-29.1% (2022) -> -3842.3% (2024)
    ✗TempletonNon-negative operating-margin trend over 3 years
    Revenue growth vs. gross and operating margin trendgross margin 88.9% -> -86.3%, operating margin -29.1% -> -3842.3%
    ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
    Net income / market capitalization-1310.67%; #6100/6340 (top 96.2%)
    ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
    Gross profit / total assets-66.10%; #3685/3702 (top 99.5%)
    ✗AsnessTop 30% of eligible cross-section
    Net income / positive book equity
    ✗AsnessTop 30% of eligible cross-section
    Negative 5-year standard deviation of ROA-13.9075; #5719/5884 (top 97.2%)
    ✗AsnessTop 30% of eligible cross-section
    3-5 Year Diluted EPS CAGR149.1% over 3 years
    ✗Neff7%-20% annualized
    Positive Diluted-EPS Years7/10 years positive
    ✓Schloss>= 70% positive over 5-10 observed years (app rule)
  • Verdicts15% pass✓ 2✗ 11▾

    Split decision: 11 FAIL · 3 NEUTRAL · 2 PASS

    Overall verdict
    ✗GrahamFAIL (2/9)✗BuffettFAIL (1/9)✗LynchFAIL (2/7)•GreenblattNot ranked✓PiotroskiPASS (F-Score 4)✗DremanFAIL (3/11)✓MungerPASS (2/4)•PabraiNEUTRAL (2/3)✗AkreFAIL (0/6)✗MarksFAIL (2/5)✗AckmanFAIL (2/9)✗TempletonFAIL (3/8)✗SleepFAIL (0/6)•AsnessNEUTRAL (Not ranked)✗NeffFAIL (1/6)✗SchlossFAIL (1/7)•OshaughnessyNEUTRAL (Not ranked)
  • Valuation31% pass✓ 9✗ 19▾

    9 of 13 flag ORGS's valuation — Graham, Greenblatt, Dreman +6 more

    Price / 3-yr avg EPS0.1x
    ✓Graham<= 15x
    Price-to-Book Ratio
    ✗Graham<= 1.5x
    P/E x P/B
    ✗Graham<= 22.5
    Basic earnings-growth PEG (dividends excluded)0.00
    ✓Lynch< 1.0 (ideally < 0.5)
    EBIT / Enterprise Value-258.9%
    ✗Greenblatt> 10%
    Earnings Yield + ROC AssessmentEY=-258.9%, ROC=N/A (invested capital <= 0)
    ✗GreenblattBoth EY > 10% and ROC > 25%
    Price / EPS0.0x
    ✓Dreman< 12x✓Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
    Price / (CFO / Shares)
    ✗Dreman< 8x
    Price / Book Value per Share
    ✗Dreman< 1.2x✗Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)
    Valuation ReasonablenessP/E=0.0x
    ✓MungerP/E < 25 or Owner Earnings Yield > 5%
    P/E or FCF YieldP/E=0.0x, FCF Yield=-471.8%
    ✓PabraiP/E < 15 or FCF Yield > 10%
    P/B or P/E vs. Historical AverageP/E=0.0x
    ✓MarksP/E < 15 or P/B < 2.0
    Discount to Intrinsic Value99.5% (IV=$69.70 vs Price=$0.38)
    ✓Marks>= 20% below intrinsic value
    Price / FCF per Share
    ✗Ackman<= 25
    Price vs. Trailing Low1705% of trailing low ($0.02)
    ✗Templeton<= 120% of trailing low (certified split-adjusted live window)
    Net income / market capitalization-1310.67%; #6100/6340 (top 96.2%)
    ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
    Positive book equity / market capitalization-10.2048; #6284/6449 (top 97.4%)
    ✗AsnessTop 30% of eligible cross-section
    Price / Diluted EPS0.0x
    ✓NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
    (EPS CAGR % + Dividend Yield %) / P/E
    ✗Neff> 0.7 (Neff's published traditional edge)
    Price / Tangible Book Value per Share
    ✗SchlossP/TBV <= 1.00x (app cutoff)
    Book Value per Share Change
    ✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
    Revenue / market capitalization+0.2816; #3405/5247 (top 64.9%)
    ✗OshaughnessyTop 10% of eligible cross-section
    (Operating cash flow - capex) / market capitalization-471.83%; #4339/4519 (top 96.0%)
    ✗OshaughnessyTop 10% of eligible cross-section
    Trailing six-month price return through the evaluation date-6.25%; #3198/6202 (top 51.6%)
    ✗OshaughnessyTop 10% of eligible cross-section
  • Growth38% pass✓ 7✗ 6▾

    5 of 8 flag ORGS's growth — Lynch, Marks, Ackman +2 more

    EPS Growth (3-yr avg, 10-yr window)15388.9%
    ✓Graham>= 33% growth
    Basic earnings-growth PEG (dividends excluded)0.00
    ✓Lynch< 1.0 (ideally < 0.5)
    3-5 Year EPS CAGR149.1%
    ✓Lynch15-30% (Fast Grower); > 0% to pass
    Inventory Growth vs Revenue Growth
    ✗LynchInventory growth < Revenue growth
    EPS Growth Direction$0.00 (2010) -> $11.44 (2024)
    ✓DremanPositive over recent years
    EPS CAGR49.7% CAGR over 12 years
    ✓Dreman> 5% annualized
    Positive Net Income Frequency2/15 years positive
    ✗MarksPositive net income in >= 7 of last 10 years
    3yr Median Revenue Growth-2.1%
    ✗Ackman>= 5%
    Positive EPS Growth Frequency4/5 years with positive EPS growth
    ✓AckmanPositive EPS growth in >= 3 of last 5 years
    5-Year EPS CAGR149.1% CAGR over 3 years
    ✓Templeton> 0% (5-year EPS CAGR)
    Revenue growth vs. gross and operating margin trendgross margin 88.9% -> -86.3%, operating margin -29.1% -> -3842.3%
    ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
    5-year Revenue CAGR-23.3%
    ✗SleepCAGR > 7%
    3-5 Year Diluted EPS CAGR149.1% over 3 years
    ✗Neff7%-20% annualized

Business & financials

Financial snapshot: annual FY 2024. Current investor scores may use newer quarterly data.

Company Profile

Industry: Pharmaceutical Products
SIC Sector: Chemicals & Pharmaceuticals
Size: Micro Cap($3.7M)
Revenue: $1.0M+95.3% YoY
Net Income: $48.2M+13.0% YoY

Financial Snapshot

Operating Margin-3842.3%
Return on Equity128.4%
Debt / Equity-0.31
Current Ratio0.03
EPS (Diluted)$11.44

Similar Companies

MRKMerck & Co., Inc.
$364.3B
ABTABBOTT LABORATORIES
$188.0B
BMYBRISTOL MYERS SQUIBB CO
$129.7B
TECHBIO-TECHNE Corp
$11.4B

Company Financials

Latest TTM and quarters alongside annual years

TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.

MetricQ3 FY 2024

2024-07-01 – 2024-09-30

Sources · derived quarter values

Derived from cumulative filings: operating cash flow, capex.

Q2 FY 2024

2024-04-01 – 2024-06-30

Sources · derived quarter values

Derived from cumulative filings: operating cash flow, capex.

Q1 FY 2024

2024-01-01 – 2024-03-31

Sources
FY 2024
Sources
  • 10-K · 2026-03-26
FY 2023
Sources
  • 10-K · 2024-04-15
FY 2022
Sources
  • 10-K · 2023-03-22
FY 2021
Sources
  • 10-K · 2022-03-30
FY 2020
Sources
  • 10-K · 2021-03-09
Market Cap$3.7Mcurrent------$98.8Mest.$613.1Mest.$760.0Mest.$1.6Best.
Revenue$347.0K$246.0K$141.0K$1.0M↑95%$530.0K↓98%$34.7M↓2%$35.5M↑364%$7.7M
Operating Income-$8.4M-$4.3M-$8.9M-$39.8M↑26%-$53.6M↓431%-$10.1M↑40%-$16.8M↑82%-$95.8M
Net Income-$9.1M-$8.9M-$9.8M-$48.2M↑13%-$55.4M↓272%-$14.9M↑18%-$18.1M↓1726%$1.1M
EPS (Diluted)$1.93$0.23$0.29$11.44↑499%$1.91↑224%$0.59↓20%$0.74↑355%$-0.29
Gross Margin-68.6%-118.7%-248.9%-86.3%↑92%-1080.2%↓1315%88.9%↑2864%-3.2%—
Operating Margin-2419.0%-1727.6%-6333.3%-3842.3%↑62%-10120.0%↓34675%-29.1%↑39%-47.3%↑96%-1251.8%
ROE———128.4%↓51%263.8%↑588%-54.0%↓15%-46.9%↓2322%2.1%
Total Debt$10.3M$6.5M$21.0M$11.8M↓40%$19.6M↑10%$17.8M↑66%$10.7M↑46%$7.3M
Shareholders' Equity-$23.9M-$15.5M-$27.7M-$37.5M↓79%-$21.0M↓176%$27.6M↓28%$38.5M↓27%$52.6M
Current Ratio0.070.070.070.03↓89%0.25↓91%2.91↑74%1.68↓45%3.08
Debt / Equity-0.43-0.42-0.76-0.31↑66%-0.93↓244%0.65↑132%0.28↑100%0.14
Operating Cash Flow-$4.6M-$5.9M-$4.4M-$17.1M↓15%-$14.8M↑40%-$24.9M↑7%-$26.9M↑66%-$78.0M
Free Cash Flow-$4.7M-$5.9M-$4.6M-$17.3M↓2%-$16.9M↑55%-$37.3M↓8%-$34.7M↑56%-$79.6M

Score history

Historical Score Timeline

Industry peers

Industry Peers

Similar companies in Pharmaceutical Products

ORGS vs Peers — Financial Grading

Revenue$1.0MBottom 25%
Net Income$48.2MBottom 25%
ROE128.4%Top 25%
D/E-0.31Top 25%
Op. Margin-3842.3%Bottom 25%
Curr. Ratio0.03Bottom 25%
CompanyMarket CapPriceRevenueNet IncomeROED/EOp. MarginCurr. RatioGrahamBuffettLynchGreenblattPiotroskiDreman
Merck & Co., Inc.MRK$364.3B$147.76$65.0B$18.3B34.7%0.94—1.542/95/94/70/3F-Score 41/11
ABBOTT LABORATORIESABT$188.0B$108.52$44.3B$6.5B12.5%0.2518.2%1.583/94/92/71/3F-Score 53/11
BRISTOL MYERS SQUIBB COBMY$129.7B$63.43$48.2B$7.1B38.2%2.4419.4%1.262/91/93/71/3F-Score 85/11
BIO-TECHNE CorpTECH$11.4B$72.80$1.2B$73.4M3.8%—8.4%3.464/93/93/70/3F-Score 54/11
REPLIGEN CORPRGEN$10.7B$167.79$738.3M$48.9M2.3%0.267.5%8.373/92/93/70/3F-Score 75/11
IONIS PHARMACEUTICALS INCIONS$4.8B$29.06$943.7M$381.4M-78.0%3.60-40.4%3.833/91/91/70/3F-Score 43/11
NEOGEN CORPNEOG$2.5B$11.23$870.4M$7.9M-0.4%0.76-2.5%3.823/91/92/70/3F-Score 64/11
Pharvaris N.V.PHVS$2.4B$33.36—$206.4M-64.8%0.00——0/90/92/70/3F-Score 22/11